Display options
Cite
Gehrke N, Wörns MA, Mann A, et al. Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation. Oncotarget. 2016;8(34):56095-56109doi: 10.18632/oncotarget.10893.
Gehrke, N., Wörns, M. A., Mann, A., Huber, Y., Hoevelmeyer, N., Longerich, T., Waisman, A., Galle, P. R., & Schattenberg, J. M. (2017). Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation. Oncotarget, 8(34), 56095-56109. https://doi.org/10.18632/oncotarget.10893
Gehrke, Nadine, et al. "Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation." Oncotarget vol. 8,34 (2017): 56095-56109. doi: https://doi.org/10.18632/oncotarget.10893
Gehrke N, Wörns MA, Mann A, Huber Y, Hoevelmeyer N, Longerich T, Waisman A, Galle PR, Schattenberg JM. Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation. Oncotarget. 2016 Jul 28;8(34):56095-56109. doi: 10.18632/oncotarget.10893. eCollection 2017 Aug 22. PMID: 28915576; PMCID: PMC5593547.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2016 Jul 28;8(34):56095-56109. doi: 10.18632/oncotarget.10893. eCollection 2017 Aug 22.

Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation.

Oncotarget

Nadine Gehrke, Marcus A Wörns, Amrit Mann, Yvonne Huber, Nadine Hoevelmeyer, Thomas Longerich, Ari Waisman, Peter R Galle, Jörn M Schattenberg

Affiliations

  1. Department of Medicine and University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  2. Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
  3. Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.

PMID: 28915576 PMCID: PMC5593547 DOI: 10.18632/oncotarget.10893

Abstract

The transcriptional nuclear factor kappa B (NF-κB)-coactivator B cell leukemia-3 (Bcl-3) is a molecular regulator of cell death and proliferation. Bcl-3 has been shown to be widely expressed in different cancer types including hepatocellular carcinoma (HCC). Its influence on hepatocarcinogenesis is still undetermined. To examine the role of Bcl-3 in hepatocarcinogenesis mice with hepatocyte-specific overexpression of Bcl-3 (Bcl-3

Keywords: B cell leukemia-3 (Bcl-3); apoptosis; hepatocellular carcinoma (HCC); mitogen-activated protein kinase (MAPK); nuclear factor kappa B (NF-kB)

Conflict of interest statement

CONFLICTS OF INTERESTS All authors declare no conflicting interests.

References

  1. Autoimmun Rev. 2012 Jul;11(9):670-7 - PubMed
  2. Cancer Cell. 2010 Mar 16;17(3):286-97 - PubMed
  3. J Hepatol. 2016 Dec;65(6):1188-1197 - PubMed
  4. Nat Med. 2011 Mar;17(3):285-6 - PubMed
  5. Mol Cell Biol. 2001 Dec;21(24):8428-36 - PubMed
  6. Oncogene. 2016 Dec 1;35(48):6203-6211 - PubMed
  7. J Hepatol. 2011 Dec;55(6):1272-80 - PubMed
  8. Gut. 2012 Dec;61(12):1733-43 - PubMed
  9. Oncology. 2007;72(1-2):97-104 - PubMed
  10. J Clin Invest. 2008 Dec;118(12):3943-53 - PubMed
  11. Leukemia. 2003 Jul;17(7):1349-56 - PubMed
  12. Oncology. 2010;78(3-4):181-8 - PubMed
  13. Nat Cell Biol. 2005 Sep;7(9):921-3 - PubMed
  14. J Hepatol. 2015 Jan;62(1):140-9 - PubMed
  15. World J Hepatol. 2010 May 27;2(5):175-9 - PubMed
  16. Cell. 2005 Jul 1;121(7):977-90 - PubMed
  17. Cancer Res. 2003 Dec 1;63(23):8293-301 - PubMed
  18. Cancer Cell. 2007 Feb;11(2):119-32 - PubMed
  19. Mol Cancer. 2009 Aug 17;8:64 - PubMed
  20. Hepatology. 2004 Feb;39(2):444-55 - PubMed
  21. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9257-60 - PubMed
  22. Cancer Res. 2003 Apr 1;63(7):1684-95 - PubMed
  23. Nature. 1992 Aug 13;358(6387):597-9 - PubMed
  24. Int J Exp Pathol. 2009 Aug;90(4):367-86 - PubMed
  25. Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141 - PubMed
  26. J Clin Invest. 2011 Nov;121(11):4268-80 - PubMed
  27. Nature. 2010 Mar 11;464(7286):302-5 - PubMed
  28. Cell. 1993 Mar 12;72(5):729-39 - PubMed
  29. Cell. 2005 Mar 11;120(5):649-61 - PubMed
  30. Patholog Res Int. 2012;2012:172894 - PubMed
  31. Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034 - PubMed
  32. Genes Dev. 2006 Jan 15;20(2):225-35 - PubMed
  33. J Biol Chem. 2016 May 13;291(20):10736-46 - PubMed
  34. Cancer Res. 2013 Jan 15;73(2):745-55 - PubMed
  35. J Biol Chem. 1999 Oct 1;274(40):28491-6 - PubMed
  36. Nat Genet. 2007 Jun;39(6):741-9 - PubMed
  37. Cancer Res. 2014 Jan 15;74(2):412-9 - PubMed
  38. Cell. 2003 Jan 24;112(2):181-92 - PubMed
  39. Cancer. 2003 Jun 15;97(12 ):3017-26 - PubMed
  40. Mod Pathol. 2004 Aug;17(8):911-7 - PubMed
  41. Nat Immunol. 2002 Mar;3(3):221-7 - PubMed
  42. J Hepatol. 2015 Apr;62(4):863-70 - PubMed
  43. Cell Death Dis. 2013 Jul 04;4:e712 - PubMed
  44. Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10544-51 - PubMed
  45. Mol Cell Biol. 2003 Jul;23(13):4713-27 - PubMed
  46. Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18 - PubMed
  47. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  48. Nat Med. 2004 Jan;10(1):48-54 - PubMed
  49. Mol Cell Biol. 1993 Jun;13(6):3557-66 - PubMed
  50. Nature. 2004 Sep 23;431(7007):461-6 - PubMed
  51. Cell. 2006 Feb 10;124(3):601-13 - PubMed
  52. Semin Cancer Biol. 2011 Feb;21(1):10-20 - PubMed
  53. Mol Carcinog. 2006 Jun;45(6):355-61 - PubMed

Publication Types